Zoetis Inc. (NYSE:ZTS) Shares Bought by Webster Bank N. A.

Webster Bank N. A. boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 89.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 174 shares of the company’s stock after purchasing an additional 82 shares during the period. Webster Bank N. A.’s holdings in Zoetis were worth $29,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Hohimer Wealth Management LLC grew its holdings in shares of Zoetis by 1.2% in the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after purchasing an additional 52 shares during the last quarter. Forum Financial Management LP increased its holdings in shares of Zoetis by 0.8% during the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after buying an additional 56 shares in the last quarter. Angeles Wealth Management LLC raised its stake in shares of Zoetis by 3.5% in the fourth quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock valued at $324,000 after acquiring an additional 56 shares during the last quarter. Prossimo Advisors LLC boosted its holdings in shares of Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares in the last quarter. Finally, River Street Advisors LLC grew its stake in shares of Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock valued at $347,000 after purchasing an additional 58 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $3.10 during midday trading on Friday, hitting $173.36. 4,189,580 shares of the company’s stock were exchanged, compared to its average volume of 2,374,760. The company’s 50 day moving average price is $168.69 and its 200 day moving average price is $178.81. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm has a market capitalization of $79.10 billion, a PE ratio of 33.40, a price-to-earnings-growth ratio of 2.74 and a beta of 0.88. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.31 EPS. As a group, analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.00%. Zoetis’s dividend payout ratio is 33.33%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group dropped their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. HSBC cut their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Barclays dropped their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.